



MARKET RELEASE

20 January 2010

Genera Biosystems Limited

TRADING HALT

The securities of Genera Biosystems Limited (the "Company") will be placed in pre-open at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in pre-open until the earlier of the commencement of normal trading on Friday, 22 January 2010 or when the announcement is released to the market.

Security Code: GBI

Gonzalo Valencia
Senior Adviser, Issuers (Melbourne)



Attention: ASX Announcement

Request for Trading Halt L.R 17.1

Melbourne, 20th January 2010

+++++

The Board of Directors of Genera Biosystems Ltd requests a Trading Halt in accordance with LR 17.1 from 10.00 a.m. on Wednesday 20th January 2010 until 10.00am on Friday 22nd January 2010.

The Trading Halt is requested by the Company pending a regulatory announcement on the status of the PapType™ HPV product. The Company expects to announce the details of these regulatory matters when trading resumes at the completion of the Trading Halt. The company is not aware of any reason why the trading halt should not be granted.

For further information please contact either

Mr Fernando Careri,
Chairman
Telephone 0418-506-289

Dr Allen Bollands
CEO
Telephone: 0423-943-600
E-mail: allen.bollands@generabiosystems.com

Signed:

Geoffrey R Widmer
Company Secretary

Web: www.generabiosystems.com

About Genera Biosystems:

Genera Biosystems Limited (ASX: GBI) is a molecular diagnostics company that develops, manufactures and distributes advanced molecular diagnostic tests. Its first product is PapType™, a test which simultaneously detects and genotypes human papillomavirus. International registrations are expected in 2010. The company has a development pipeline of products including novel tests for *Chlamydia trachomatis*, and *Neisseria gonorrhoea*.